Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is performed as a curative option in adult T-cell leukemia-lymphoma (ATL) patients, its high transplantation-related mortality raises a serious issue. infection at 3 years was 69.2% in ATL patients versus 54.4% in AML patients (p=0.0255). Cumulative infection-related mortality was significantly higher in ATL patients than that in the two other groups (ATL vs AML, p=0.0496; ATL vs ALL/LBL, p=0.0075), and most death-causing pathogens were bacteria and fungus. The appearance of CMV infection was negatively associated with infectious mortality in ATL patients, but the P-value for this association was near the borderline of significance (p=0.0569). In multivariate analysis, transplantation using unrelated bone marrow and episodes of CMV infection were associated with worse overall survival in ATL patients, but were not in either AML or ALL/LBL patients. Collectively, the impact of infectious complications after transplantation in ATL patients was different from that in AML and ALL/LBL patients, suggesting that a more intensive strategy for infection control in ATL patients is required to reduce infectious mortality.
INTRODUCTION

Adult T-cell leukemia-lymphoma (ATL) is a peripheral T-cell neoplasm caused by
human T-cell lymphotropic virus type I (HTLV-I) [1] [2] [3] [4] . The clinical feature of ATL is heterogeneous and is characterized by various degrees of lymphadenopathy, abnormal lymphocytosis, hepatosplenomegaly, skin lesions, and hypercalcemia dividing the disease into 4 subtypes: acute, lymphoma, chronic, and smoldering [5] . Over the past decade, allogeneic hematopoietic stem cell transplantation (allo-SCT) was performed in young patients with aggressive ATL (acute, lymphoma, unfavorable chronic type) in Japan because aggressive ATL shows resistance to a variety of cytotoxic agents and has a poor outcome [6, 7] . Several reports demonstrated that allo-SCT provided apparent long-term remission in some patients, along with the graft-versus-ATL effect [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
However, transplantation-related mortality (TRM) was higher than that observed for acute leukemia (acute myeloid leukemia; AML, acute lymphoblastic leukemia/lymphoblastic lymphoma; ALL/LBL), especially within 6 months of allo-SCT [10, 14] .
In general, ATL patients are susceptible to various opportunistic infections, including
Pneumocystis jirovecii pneumonia (PJP), invasive fungal infections, and herpes virus diseases due to defective cellular immunity. Suzumiya et al. reported that cytomegalovirus (CMV) was involved in 35 of 47 autopsied cases of ATL and that CMV pneumonia was a significant cause of death [18] . Furthermore, it has been reported that development of PJP, invasive fungal infection, and herpes virus disease are more frequent in ATL patients [19] [20] [21] [22] . Collectively, infectious complications in patients with ATL may be different from those in patients with acute leukemia or malignant lymphoma, during allo-SCT. Recently, a nationwide retrospective study in Japan pointed out that infectious mortality was a main cause of TRM after transplantation for ATL [14] . However, there are no differences in prophylaxis and treatment for infection between ATL and other hematological diseases during the allo-SCT procedure. It remains unclear whether the current strategy for infection is sufficient or not for post-transplant patients with ATL because of the lack of detailed information for infectious complications after allo-SCT in these patients.
In the present report, we retrospectively analyzed 210 post-transplant patients with ATL, AML, or ALL/LBL to clarify differences in the clinical features of infectious complications after allo-SCT for patients with ATL.
PATIENTS AND METHODS
Patient population
In this study, adult patients aged 16 years or older that received allo-SCT at 3 hospitals in Nagasaki prefecture with the diagnosis of AML, ALL/LBL, or ATL were included.
These patients underwent allo-SCT between September 1997 and December 2009. Of 228 patients whose data were available, 18 were excluded because of death without neutrophil engraftment. The remaining 210 patients were included in the analysis. This study was approved by the Ethical Committees of the participating hospitals.
Definition of clinical end points and responses
Neutrophil engraftment was defined by the recovery of an absolute neutrophil count of at least 0.5×10 9 /L for 3 consecutive points; platelet recovery was defined by the recovery of a count of at least 500×10 9 /L without transfusion support. Diagnosis and clinical grading of acute and chronic graft-versus-host diseases (aGVHD and cGVHD)
were performed according to established criteria [23, 24] .
For ATL patients, response to treatment was divided into four categories: complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). Responses were defined as follows: CR, disappearance of all disease; PR, ≥50% reduction in measurable disease; SD, failure to attain CR, PR, and no PD; PD, any new lesions or lesions with proliferation (increases in the size and number of abnormal cells).
For acute leukemia patients, CR was defined as the presence of all of the following:
fewer than 5% blasts in bone marrow, no leukemia blasts in peripheral blood, recovery of peripheral neutrophil counts to more than 1.0×10 9 /L and platelet counts to more than 100×10 9 /L, and no evidence of extramedullary leukemia.
Prophylaxis of infection, and monitoring and preemptive therapy for CMV diseases
During the allo-SCT procedure, each patient was treated in a reverse isolation room, which was ventilated with a high-efficiency particulate air filtration system. As prophylaxis of fungal infection, itraconazole (200mg/day) was generally administered to most patients from the start of conditioning [25, 26] . In the cases of itraconasole intolerance due to its adverse effect, in principle, fluconazole (100mg/day) was administered before 2004 and micafungin (50mg/day) after 2005 when micafungin became widely available for prophylaxis in Japan. If these drugs could not also be tolerated, either amphotericin B or voriconazole was administrated in accordance with the institutional strategy. Prophylaxis against PJP was performed primarily with oral trimethoprim-sulfamethoxazole (ST) [25] . All patients received prophylactic antibodies (ceftazidime or ciprofloxacin) once absolute neutrophil counts had become less than 0.5×10 9 /L [25, 27] . Acyclovir (1000mg/day) was used for the prevention of diseases by the Herpes Simplex virus (HSV) and Varicella Zoster virus (VZV) until day 100 after transplantation [25, 28] . After the recovery of neutrophils, CMV pp65 antigen in peripheral blood was monitored weekly through day 100 after transplantation to detect CMV antigenemia [29] . The CMV antigenemia test was considered positive if at least one positive-stained cell per 5.0 × 10 4 cells was detected on the slides. Preemptive therapy was initiated when CMV antigenemia became positive. In most cases, ganciclovir (GCV) was administrated at an induction dose of 5mg/kg intravenously every 12 hours as preemptive therapy [30, 31] . After antigenemia had been eliminated, GCV was either discontinued immediately or continued for a short time at a maintenance dose, in accordance with the institutional strategy. Based on the prevalence of high positivity for CMV antibody among Japanese [32, 33] , the evaluation of CMV-serostatus before transplantation was depended on the institutional strategy.
Instead, for prophylaxis of CMV, all patients received irradiated blood products which were depleted of leukocytes by filters [34] . No patient was transfused with CMV-seronegative blood components.
Fungal infections
Invasive fungal infections were divided into candidemia, invasive aspergillosis, and apparent organ damage by other fungi or molds [35] . 
CMV infection and CMV disease
Diagnosis of CMV infection and CMV disease was made based on previously described criteria [36] . In brief, CMV disease was defined by the presence of clinical signs and/or symptoms of end-organ disease combined with the detection of CMV infection in a biopsy specimen or bronchoalveolar lavage fluid in case of pneumonia.
CMV infection was defined as the isolation of a virus or detection of viral protein or nucleic acids in any body fluid or tissue specimen. CMV infection included both CMV antigenemia and CMV disease.
Viral infections other than CMV
Patients who were culture-or polymerase chain reaction (PCR)-positive for adenovirus (ADV) with corresponding clinical signs and symptoms were considered to have an ADV infection involving those sites [37] . BK virus infection was defined as hemorrhagic cystitis with positive PCR results in urine samples [38] , and for human herpes virus-6 (HHV-6) infection, detection of the virus genome by PCR from blood and/or cerebrospinal fluid [39] .
Statistical analysis
The Kaplan-Meier method was used to estimate overall survival (OS) after allo-SCT.
The 95% confidence interval of 3-year OS was calculated. To illustrate the effects of cGVHD on OS, OS was measured from a predefined 'landmark' time of 100 days after allo-SCT when analyzing the effect of this factor. Probabilities between subgroups were compared by means of the log-rank test. Cumulative incidences of infectious complications and infection-related death were calculated using Gray's method, considering deaths related to relapse or other complications than infection as a competing risk.
Furthermore, simultaneous effects of prognostic factors on OS were analyzed using multivariate regression analysis based on the Cox's proportional hazards model and linear logistic model, respectively. Variables considered were age of the patient at transplantation, sex of the patient, donor type, disease status at conditioning, and the t(9;22) chromosome abnormality or others for ALL/LBL, cytogenetic risk group defined by the MRC group [40, 41] for AML and French-American-British (FAB)
classification of M0/M6/M7 or others for AML, clinical subtypes according to criteria of the Japanese Lymphoma Study Group for ATL [5] , the incidence of CMV infection, disease and antigenemia, bacterial infection, fungal infection, viral infection other than CMV, aGVHD, the conditioning regimen, and institution where patients received allo-SCT. The most appropriate models were selected based on Akaike's information criteria (AIC). All analyses were performed using SAS version 9.2 software (SAS Institute, Cary, NC, USA). Values of P<0.05 were considered significant in all analysis.
RESULTS
Patient characteristics and transplant conditions
In 228 patients who received allo-SCT in our study, 7 AML, 2 ALL/LBL, and 9 ATL patients experienced graft failure and/or rejection. The rate of graft failure and/or rejection was not statically difference among each 3 groups.
The characteristics of remaining 210 patients are shown in Table 1 . All ATL and ALL/LBL patients received standard-dose chemotherapy before the procedure of transplantation, but 10 AML patients did not receive any chemotherapy before allo-SCT.
Sixteen related donors for ATL patients showed a positive result for the anti-HTLV-1
antibody. Peripheral blood mononuclear cells of these donors were subjected to Southern blot analysis to examine the monoclonal integration of the HTLV-1 provirus into the genome, and all 16 donors were confirmed as carriers of HTLV-1.
ATL patients were older and were more likely to receive reduced intensity conditioning regimens than patients with AML or ALL/LBL. Reduced-intensity conditioning using anti-thymocyte globulin was administered to two ATL patients. In general, HLA matched unrelated bone marrow recipients were more likely to receive tacrolimus-based GVHD prophylaxis than those who received allo-SCT using other stem cell sources. No patients received in vitro T cell-depleted transplantation. The procedure of prophylaxis for fungal infection was similar among 3 groups.
The median time to engraftment were 16 days (range, 7-29 days), 16 days (range, 
CMV antigenemia, disease, and infection
The characteristics of CMV infection (CMV antigenemia and CMV disease) are shown in 13.5-34.0%) in ATL groups. The ATL group showed the highest cumulative incidence of bacterial infection, but there was no significant difference among the three groups (data not shown). Serious bacterial infections were documented among 37 patients (sepsis, n=27; pneumonia, n=9; meningitis, n=1). Three ATL patients exhibited
Pathogens other than CMV that caused clinical infection after transplantation
Pseudomonas aeruginosa infection (pneumonia, n=2; sepsis, n=1), but none did in AML and ALL/LBL groups.
Cumulative incidence of fungal infection at 100 days and 1 year were followed; 2.2% (95% CI: 0.4-7.0%) and 5.8% (95% CI: 2.1-12.2%) in AML groups, 2.0% (95% CI:
0.2-9.3%) and 6.4% (95% CI: 1.6-16.1%) in ALL/LBL groups, and 7.5% (95% CI:
2.7-15.5%) and 9.4% (95% CI: 3.8-18.2%) in ATL groups. The ATL group showed the highest cumulative incidence of invasive fungal infection, without a significant difference among the three groups (data not shown). In total, 3 patients (2 ATL patients and 1 ALL/LBL patient) developed PJP without prophylactic ST, but none did in the AML group even without ST prophylaxis. Two ATL patients developed PJP with CR, respectively, at day 18 and 137 after allo-SCT. One ALL patient also developed PJP coincident with relapsed disease at day 392 after allo-SCT.
Cumulative incidence of viral infection other than CMV at 100 days and 1 year were 
Death caused by infections
Cumulative infection-related mortalities at 100 days and 1 year were followed; 2.3% (95% CI: 0.4-7.2%) and 6.1% (95% CI: 2.2-12.7%) in AML groups, 0.0% (95% CI:
0.2-9.5%) and 2.0% (95% CI: 0.2-9.5%) in ALL/LBL groups, and 9.4% (95% CI:
3.8-18.2%) and 14.7% (95% CI: 7.1-24.8%) in ATL groups. The ATL group showed the highest mortality, which was significantly greater than that of the other two groups (AML vs ATL, p=0.0496; ALL/LBL vs ATL, p=0.0075) (Figure 1a) . However, in all 210 patients, ATL was not a significant factor despite the high hazard rate for infection-related mortality on multivariate analysis (Hazard rate (HR) 2.283; 95%
confidence interval (CI): 0.834-6.251, p=0.1083); multivariate analysis revealed that non-remission at allo-SCT was a significant unfavorable factor for infection-related mortality (HR 2.528; 95% CI: 1.007-6.345, p=0.0482).
While non-remission at allo-SCT remained a significant risk factor for infection-related mortality in AML group, this factor did not in ALL/LBL and ATL groups. Rather, in the ATL group, infection-related mortality was higher among patients who experienced a CMV infection after allo-SCT than those who did not, but the P-value was at the borderline of significance (p=0.0569) (Figure 1b ). There was no significant relationship between episodes of CMV infection and mortality caused by infection in either the AML or ALL/LBL group (AML group, p=0.3160; ALL/LBL group, p=0.4461). Additionally, to exclude the bias due to the CMV-serostatus of patients, infection-related mortalities were analyzed in patients with CMV-seropositive of each 3 groups. For CMV-seropositive patients, the comparison of cumulative infection-related mortalities between those with episodes of CMV infection and without showed a significant difference in ATL group; the episodes of CMV infection have a significant negative impact on infection-related mortalities in the ATL group (p=0.0492),
but not in the AML and ALL/LBL groups (p=0.0840 and p=0.4276, respectively).
The difference of institution did not have any impact on the cumulative infection-related mortalities in each 3 groups. In ATL group, the HTLV-1 serostatus of donor was not associated with cumulative infection-related mortalities.
The pathogens resulting in fatal infectious complications are shown in Table 4 .
Interestingly, despite the high incidence of CMV infection after allo-SCT, only 4 patients died of CMV diseases (CMV pneumonia in 2 ATL and 2 AML patients), and no ALL/LBL patient died of any CMV disease. Of these 4 patients, one AML and one ATL patients died of recurrent CMV infection on late phase. In the patients who died of infection on late phase, 4 out of 6 ATL, 1 out of 4 AML and no ALL/LBL patients died of bacterial infection. The proportion of bacteria in the pathogens resulting in fatal infectious complications on late phase after allo-SCT was likely to be higher in ATL group than in each AML and ALL/LBL groups, but this difference was not significant.
The pathogens inducing fatal complications in 4 ATL patients on late phase were either methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, which were resistant to many antibiotic agents. Also, these 4 ATL patients experienced the improvement of CMV antigenemia by GCV on post-engraftment phase (ie. before the development of fatal bacterial infections).
Survival
The outcomes of allo-SCT in each 3 groups are shown in Table 5 . Median survival times after allo-SCT were 4.0 years and 1.0 year in the AML group and ATL group, 
respectively. Median survival was not reached in the ALL/LBL group (Figure 2a
)
Univariate analysis for survival
Univariate analysis for survival identified several pretransplantation and There was no significant relationship between the difference of institution and OS in each 3 groups. For the ATL group, neither the use of anti-thymocyte globulin in the conditioning regimen nor the HTLV-1 serostatus of donor was associated with survival.
Multivariate analysis for survival
Multivariate analysis in all 210 patients revealed 6 factors that adversely affected OS: 
DISCUSSION
The success or failure of allo-SCT is mostly determined in the first 6 months after allo-SCT. Outcome closely correlates with the reconstitution of donor cell derived immunity, which affects the survival of recipients through GVHD and the graft-versus-leukemia effect, and the degree of immune competence achieved against infectious agents. Recently, some reports have indicated that the incidence of fungal infection and CMV infection has increased after engraftment, particularly among patients with severe immunodeficiency. For example, after allo-SCT using in vitro or in vivo T-cell depletion, fungal infection, and reactivation of the Epstein-Barr virus and CMV are closely related to serious complications [42] [43] [44] [45] [46] [47] [48] [49] . Also, the risk of infectious complications, including HHV-6 encephalitis and CMV diseases, is higher in patients who received cord blood transplantation [42, [50] [51] [52] [53] [54] . These results suggested that the incidence of infectious complications depends not only on infectious disease-causing pathogens but also on the background of the patient or the cause of immunosuppression.
In our study, while the cumulative incidence of either bacterial or fungal infection was similar among the three groups, the ATL group showed the highest cumulative incidence of infection-related death, mainly caused by these infections. Importantly, bacteria resistant to many antibiotic agents emerged as a cause of death after 100 days in ATL patients. It is suggested that ATL patients after allo-SCT would be more susceptible to life-threatening bacterial infections even on late phase than those with acute leukemia, and that the current strategy for infection would not be sufficient for allo-SCT to ATL.
Hence, it seems that the development of an adoptive strategy in post-transplant patients with ATL is required.
The appearance of a CMV infection showed a negative impact for OS as an independent variable in the ATL group. Interestingly, while there were only 2 ATL patients having CMV disease at the time of death, the risk of infectious death in ATL patients who experienced CMV infection (that included CMV antigenemia) was likely to be higher. Namely, episodes of CMV infection could predict a higher risk of death caused by not only CMV disease, but also other infections, which may help to identify the ATL patients that should receive more intensive management for infection.
It is not clear why episodes of CMV infection correlated with the outcome of ATL patients, although multivariate analysis identified episodes of CMV infection as an independent variable only in the ATL group. It has been shown that episodes of CMV infection were associated with a worse outcome in post-transplant patients with defective cellular immunity [43, 44, 55] . Therefore, it is speculated that persistent compromised cellular immunity after transplantation led to the higher susceptibility of CMV and other infections among ATL patients, resulting in worse outcomes than leukemia patients. Considering that the reactivation of CMV itself and the prolonged administration of GCV were thought to induce greater immune suppression [56, 57] , we hypothesize that the direct and indirect influence of CMV infection adversely promoted immunosuppression attendant on ATL patients. It remains to be elucidated how immunologic recovery was delayed after transplantation in ATL patients. Since the immune system recovery following allo-SCT was not sufficiently evaluated in our study, the monitoring of immune function after transplant, such as analysis of lymphocyte subset and quantitative estimation of immunoglobulin, should be considered in a future study.
It is possible that CMV-serostatus affected the result of statistical analysis in our study, because CMV-serostatus, which was unexamined in 37.6% patients, was not included in the statistical analysis. Therefore, to remove the bias of this point, the analysis for ATL patients with CMV-seropositive revealed that CMV infection was also identified as a risk factor in infection-related mortality and OS. Considering that it has been reported that about 90% Japanese showed CMV-seropositive, the difference of CMV-serostatus would not have a big impact in our study. However, a larger analysis for matched patient's background regarding with CMV-serostatus would help to confirm our findings.
ATL group showed that the highest cumulative incidence of infection-related mortality and the various pathogens causing death, indicating that it was difficult to establish the uniform management to reduce the fetal infectious complications for post-transplant patients with ATL. However, it is speculated that more intensive management for bacterial infection might provide the reduction of infection-related death in some post-transplant patients with ATL, since ATL group would be more likely to show the higher risk of fetal antibiotic-resistant bacterial infection even on late phase in our study.
Therefore, appropriate antibiotic treatment using prolonged bacterial surveillance culture should be considered, particularly in ATL patients with persistent compromised cellular immunity. Moreover, because of a limitation of treatment active on multi-drug resistant gram negative rods, particularly Pseudomonas aeruginosa, at the present situation, the introduction of new treatment options, including antibiotic combination therapy using a "break-point checker board plate" and developing antibiotic agents such as colistin [58] [59] [60] [61] [62] , are expected in patients who developed such infection after allo-SCT.
Our results showed the higher risk of fetal infectious complications in post-transplant patients with ATL. However, the number of patients is limited and the detailed treatment protocols were not completely uniform. Thus, it is possible that these factors exerted a bias and affected results: for instance, the small number of patients in our study resulted in wide and overlapping confidence intervals despite P values <0.05. Out finding should be interpreted carefully, and they should be confirmed in larger prospective studies.
In conclusion, we found that the clinical features of infectious complications after allo-SCT in ATL patients are different from those in AML and ALL/LBL patients.
Because allo-SCT offers the best chance of prolonged survival by inducing graft-versus-ATL effect, developing supportive care to minimize fatal infectious complications would be important, in particular, for post-transplant patients with ATL.
Our data suggested that ATL patients require more intensive management for infections according to individualized risk such as the appearance of CMV infection. Such a strategy may be beneficial in reducing TRM in post-transplant patients with ATL.
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MRSA indicates methicillin-resistant Staphylococcus aureus. In the ATL group, episodes of CMV infection significantly correlated with worse OS. However, there was no such association in either the AML or ALL/LBL group.
Figure 1. Cumulative incidence of infection-related death after transplantation
